جست‌وجوی استاد و پژوهشگر

Mariko L Bennettمشاهده پروفایل

استادیار

• Microglia
• Neuroimmunology
• Neuroinflammatory Diseases
• +۳ مورد دیگر

Dr. Mariko L Bennett serves as Assistant Professor of Neurology and Pediatrics at the Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania, where she leads the Mariko Bennett Lab focused on microglial biology in pediatric neuroimmunological diseases. Her research integrates clinical neurology with basic science to develop novel therapeutic approaches for conditions like leukodystrophies and Aicardi-Goutières Syndrome. Her primary research investigates microglia—the brain's resident macrophages—in neurodevelopment and disease, with emphasis on therapeutic microglia replacement, viral gene therapy engineering, and human disease modeling. The lab employs cutting-edge techniques including single-cell transcriptomics and engineered disease models to elucidate glial contributions to neuroinflammation and identify intervention points for pediatric neurological disorders. Recent publications demonstrate consistent focus on microglia replacement therapies for monogenic neurological diseases, with emerging themes in neuroimmune crosstalk, seizure modulation, and leukodystrophy mechanisms. Her work bridges fundamental glial biology with translational applications, particularly in pediatric contexts where neurodevelopmental timing is critical. Scientific recognition includes: NIH Director’s Early Independence Award (2023) CHOP Faculty Honor Roll for resident education (2024) Klaus Hummler High Impact Award for Immunity publication (2025) Dr. Bennett mentors four PhD candidates in Penn's Neuroscience Graduate Group and Gene Therapy program, alongside undergraduate researchers. Her lab secured an R01 grant for Aicardi-Goutières Syndrome research and develops shareable tools for the neuroimmunology community. Current funding supports microglia-targeting therapeutic development and humanized disease modeling. The lab operates within CHOP's Leukodystrophy Center of Excellence with strong ties to the Global Leukodystrophy Initiative (GLIA) and collaborative networks including the Chris Bennett Lab and Shane Liddelow Lab. Team members actively participate in Gliadelphia initiatives and Cold Spring Harbor Laboratory meetings, maintaining a dynamic environment focused on translating microglial discoveries into clinical applications for pediatric neurological disorders.

Aime T. Francoمشاهده پروفایل

استادیار

• Molecular biology
• Genetics
• Thyroid cancer
• +۵ مورد دیگر

Aime T. Franco, PhD, serves as an Assistant Professor of Pediatrics at the Perelman School of Medicine, University of Pennsylvania, and as an Investigator at the Children's Hospital of Philadelphia (CHOP). She directs the newly established Pediatric Thyroid Cancer Translational Research Laboratory and holds affiliations with CHOP's Pediatric Thyroid Center and Endocrinology and Diabetes team, focusing on bridging clinical care with molecular research in pediatric thyroid disorders. Her educational foundation includes a PhD in Cancer Biology from Vanderbilt University, an MS in Nutritional Sciences from the University of Connecticut, and a Postdoctoral Fellowship in Genetics of Thyroid Cancer at Memorial Sloan Kettering Cancer Center. These credentials underpin her expertise in cancer mechanisms and translational applications. Dr. Franco's research program centers on the molecular biology and genetics of thyroid cancer, with particular emphasis on tumor microenvironment dynamics, genetic drivers like BRAF and HRAS mutations, and Helicobacter pylori-related carcinogenesis. Her work extends to improving quality of life and survivorship outcomes for thyroid cancer patients through mechanistic studies of metastasis, immune suppression, and cellular plasticity. This dual focus on basic molecular pathways and patient-centered outcomes defines her translational approach. Analysis of her 15 most recent publications reveals consistent investigation into thyroid cancer progression mechanisms, with significant contributions to understanding fibroblast-mediated collagen remodeling, lymph node structural alterations preceding metastasis, and platelet roles in cancer biology. Her work spans from nanoscale cellular imaging to clinical surgical applications, demonstrating methodological breadth while maintaining disease-specific focus. Her scientific recognition includes 13 major awards such as the American Cancer Society Leadership Summit participation, Endocrine Society Outstanding Abstract Award, NIH National Research Service Award, and multiple first-place presentation honors at Vanderbilt University. These reflect sustained excellence from graduate training through her independent career. As an active journal reviewer for over 15 publications including Cancer Research and Endocrinology, Dr. Franco contributes significantly to scholarly discourse. While specific student mentorship details aren't publicly documented, her leadership roles in the American Thyroid Association's Pediatric Thyroid Cancer Guideline Task Force and Diversity, Equity and Inclusion Taskforce indicate substantial professional service. Her laboratory at CHOP functions as an integrated research hub connecting molecular discoveries with clinical applications for pediatric thyroid cancer patients.

• Translational Cancer Research
• Lung Cancer
• Prostate Cancer
• +۳ مورد دیگر

Samer Al-Saad serves as an Associate Professor in the Department of Medical Biology at UiT The Arctic University of Norway, Tromsø campus. He is an active member of the Research Group for Translational Cancer Research (IMB/IKM), contributing significantly to the university's cancer research profile through his work on molecular mechanisms and biomarker discovery in oncology. Dr. Al-Saad's research program focuses on critical areas in cancer biology, with particular emphasis on lung and prostate cancers. His work explores: Translational research bridging laboratory findings to clinical applications Identification and validation of prognostic and predictive biomarkers Tumor immunology and microenvironment characterization Molecular pathways influencing cancer progression and treatment resistance Gender-specific differences in cancer biology and outcomes MicroRNA expression patterns as diagnostic and prognostic tools Analysis of Dr. Al-Saad's publication history reveals a consistent focus on refining cancer staging and prognostication through novel biomarkers. His recent work particularly emphasizes immune cell infiltration patterns in non-small cell lung cancer, with multiple studies examining tertiary lymphoid structures, tumor-infiltrating lymphocytes, and immune checkpoint molecules as predictors of patient outcomes. He frequently employs advanced pathological techniques including multiplex immunohistochemistry to characterize the tumor microenvironment with high spatial resolution. Dr. Al-Saad maintains an extensive collaborative network, as evidenced by his numerous co-authored publications in high-impact journals. His research has practical implications for improving cancer diagnosis, prognosis, and potentially treatment selection through biomarker development, with recent contributions appearing in the New England Journal of Medicine, British Journal of Cancer, and Scientific Reports.

Theo van den Broekمشاهده پروفایل

استادیار

• Immunology
• Translational Research
• T cells
• +۴ مورد دیگر

Theo van den Broek is an Assistant Professor at the Center for Translational Immunology (CTI), Utrecht University. A physician-scientist trained in medical microbiology and immunology, he leads an independent research group investigating T/B cell interactions. He holds a PhD from Utrecht University (2015) and completed postdoctoral training at Harvard Medical School through a Marie Curie Global Fellowship. His research bridges fundamental immunology and clinical applications, focusing on: Dynamic interactions between T and B cells in lymphoid tissues Pediatric immune system development Loss of immune tolerance in autoimmune diseases Translational approaches for infectious disease management Publications primarily explore germinal center biology, B cell clonality, and autoimmune mechanisms, with recent work extending to metabolic genetics and science education policy. His immunological studies consistently employ human tissue models and advanced genomic techniques. Awarded significant honors including: Marie Curie Global Fellowship for autoimmune research VENI Fellowship for pediatric immunology investigations Leads the research group 'T:B cell interactions in human lymph nodes' aiming to transform clinical immunology through lymph node studies.

Sergey Krysovمشاهده پروفایل

دانشیار

• Immunogenetics
• B cell malignancies
• Chronic Lymphocytic Leukemia
• +۵ مورد دیگر

Dr. Sergey Krysov serves as Reader in Molecular Biology and Group Leader at the Barts Cancer Institute, Queen Mary University of London. He holds the position of Director of Undergraduate Studies for the institute and is an active member of the European Research Initiative on CLL (ERIC). His academic role encompasses research leadership, undergraduate program oversight, and specialized teaching in hemato-oncology. Dr. Krysov's research centers on immunogenetics of B-cell malignancies, with primary focus on chronic lymphocytic leukemia (CLL) and follicular lymphoma. He investigates B-cell receptor (BCR) signaling pathways, immunoglobulin glycosylation patterns, and tumor microenvironment interactions. His work spans cancer prevention mechanisms, targeted tumor cell therapies, and cell signaling dysregulation, with particular emphasis on how acquired N-glycosylation sites drive lymphoma evolution and how lectin binding triggers persistent BCR activation. Analysis of his 15 most recent publications (2014-2025) reveals consistent thematic focus on BCR signaling abnormalities in CLL and follicular lymphoma. Key research trajectories include CD180 expression patterns across anatomical compartments, EMT-like activation as a therapeutic target, metabolic reprogramming through glycolysis enhancement, and microbiome interactions via bacterial lectins. His work demonstrates translational potential through identification of novel biomarkers and therapeutic vulnerabilities. Scientific recognition includes: John Goldman Fellowship for Future Science (Leuka, 2016-2018) Dr. Krysov has secured substantial research funding including a Barts Charity Strategic Research Grant (2016-2020, £77,487) investigating peripheral blood composition in CLL patients, a Leuka fellowship (2016-2018, £100,000) studying the BCR-ZEB2 axis, and current Barts Charity project (2021-2024, £256,000) examining EMT-like activation in B-cell malignancies. He leads teaching modules BMD211 Human Molecular Biology and CANM935 Molecular Targeted Therapies for Blood Cancers. As Group Leader within the Centre for Haemato-Oncology Research, he directs a multidisciplinary team utilizing genomic sequencing, primary patient samples, and xenograft models to dissect molecular mechanisms of B-cell malignancies, with current emphasis on therapeutic targeting of EMT-like pathways and microbiome-BCR interactions.

• Stem cell biology
• Cell-based therapy
• Cancer stem cells
• +۳ مورد دیگر

Eric Lagasse is a Professor of Pathology in the Division of Experimental Pathology at the University of Pittsburgh School of Medicine and a member of the McGowan Institute for Regenerative Medicine. With a PharmD from Louis Pasteur University (1985) and a PhD from the University of Basel (1989), Dr. Lagasse has established himself as a leading researcher in stem cell biology and regenerative medicine. Dr. Lagasse's research focuses on stem cell biology and cell-based therapy for various diseases, with particular emphasis on liver disease treatment , ectopic organogenesis , and cancer stem cell identification . His groundbreaking work has demonstrated the potential of using lymph nodes as sites for ectopic organ development, including liver and kidney regeneration. Analysis of Dr. Lagasse's publication record reveals a consistent focus on stem cell applications in regenerative medicine and cancer research. His early work established foundations in stem cell transplantation, while more recent publications explore the theoretical frameworks for future regenerative medicine approaches. The research spans disciplines including molecular biology, tissue engineering, and oncology, with increasing emphasis on systems-level understanding of cellular regeneration. Dr. Lagasse maintains an active research program with publications spanning over three decades, demonstrating sustained contributions to the field of regenerative medicine. His work bridges basic science and potential clinical applications, particularly in developing alternative approaches to organ transplantation. Based in the McGowan Institute for Regenerative Medicine at the University of Pittsburgh, Dr. Lagasse's laboratory continues to explore innovative approaches to tissue engineering and stem cell therapy, with potential applications for treating liver failure, kidney disease, and cancer.

• Endocrinology
• Metabolism
• Obesity Research
• +۳ مورد دیگر

Kirsi Virtanen serves as Assistant Professor (Phase II) at the University of Turku's PET Center, where she leads research at the intersection of endocrinology, metabolism, and advanced imaging. Her work focuses on human metabolic physiology with emphasis on adipose tissue biology, obesity mechanisms, and liver disease pathogenesis. Research interests center on brown adipose tissue thermogenesis , gut-liver-metabolite interactions , and metabolic imaging . She investigates how short-chain fatty acids serve as brown fat biomarkers, how cryotherapy impacts obesity management, and the role of lymphoid structures in adipose tissue inflammation. Her methodology combines clinical PET imaging with molecular metabolomics to dissect metabolic pathways in human disease. Analysis of her 2024-2025 publications reveals a strong translational trajectory, with 9 high-impact papers spanning original clinical research, imaging methodology, and mechanistic reviews. Key trends include growing emphasis on microbiome-derived metabolites in metabolic disease, refinement of PET techniques for metabolic phenotyping, and expansion into immunometabolism through lymphoid-adipose tissue crosstalk studies. Dr. Virtanen maintains active international collaborations across Europe and North America, particularly in obesity genetics and imaging methodology. Her clinical trial work suggests strong grant support for human metabolic studies, and she likely supervises graduate students in endocrinology and nuclear medicine. Prospective researchers should contact her directly regarding lab opportunities in metabolic imaging and translational obesity research.

Alexei Tumanovمشاهده پروفایل

دانشیار

• Immunology
• Molecular Immunology
• Cancer Immunology
• +۳ مورد دیگر

Alexei Tumanov, M.D., Ph.D., serves as an Associate Professor in the Department of Microbiology, Immunology & Molecular Genetics at the University of Texas Health Science Center at San Antonio (UTHSCSA) School of Medicine. Recruited in Fall 2016 after establishing his research lab at Trudeau Institute (NY) in 2011, he maintains laboratory space in the MED building (5.018V). His academic journey began at Russian State Medical University (M.D.), followed by Ph.D. training at Engelhardt Institute of Molecular Biology, and postdoctoral work with Dr. Yang-Xin Fu at University of Chicago. Russian State Medical University: M.D. Engelhardt Institute of Molecular Biology: Ph.D. in Molecular Biology University of Chicago: Postdoctoral Training Dr. Tumanov's research program investigates immune system regulation of protective immunity versus immunopathology, combining molecular data with in vivo models to develop immunotherapies. His work spans lymphoid organ development, cytokine networks (particularly lymphotoxin pathways), neuro-immune interactions, and cancer immunology. The lab demonstrates consistent productivity with publications in high-impact journals including Nature, Science Immunology, and Cancer Cell. Analysis of his recent publications reveals a strong focus on lymphotoxin signaling pathways across multiple disease contexts - from pancreatic cancer tertiary lymphoid structures to asthma pathogenesis and lymph node development. His work consistently bridges fundamental immunology with translational applications, particularly in inflammation regulation and immune cell trafficking mechanisms. Dr. Tumanov maintains active collaborations across immunology research centers, evidenced by co-authorships with institutions including Jackson Laboratory, NCI-Frederick (NIH), and multiple European research groups. His lab appears to focus on both innate lymphoid cell biology and stromal-immune interactions within tissue microenvironments.

• Head and Neck Cancer
• Radiation Oncology
• Cancer Immunotherapy
• +۴ مورد دیگر

Stuart J. Wong, MD, is Professor of Hematology/Oncology and Otolaryngology at the Medical College of Wisconsin (MCW). He serves in multiple leadership roles including Director of the Center for Disease Prevention Research, Program Leader of the Head and Neck Cancer Disease Oriented Team, and Chair of the MCW Cancer Center Investigator Initiated Trial Steering Committee. His hospital privileges include Froedtert Memorial Lutheran Hospital and Zablocki VA Medical Center. His research focuses on: Head and neck cancer therapeutics including chemoradiation and reirradiation strategies Immuno-oncology approaches and precision medicine targets Radiation sensitization mechanisms and fractionation optimization Novel biomarker development and translational applications Cancer prevention methodologies Publication analysis reveals concentrated work in radiation therapy optimization, immunotherapy combinations, and molecular determinants of treatment response in head and neck cancers. Recent studies emphasize precision oncology, tumor microenvironment modulation, and advanced imaging-guided radiotherapy. Honors and awards: RTOG Next Generation Investigator Award (2008) MCW Outstanding Faculty Service Award (2011) U.S. News and World Report Best Doctors (2011-2017) M Magazine Top-Rated Doctors (2013) Medical College of Wisconsin Eminent Scholar (2019) He leads multiple NCI-funded clinical trials and serves on steering committees for NRG Oncology and RTOG. Current grants focus on head and neck cancer treatment optimization, targeted therapies, and radiation-immune interactions. He coordinates multidisciplinary teams across hematology/oncology, radiation oncology, and otolaryngology departments.

• Dermatopathology
• Pathology
• Anatomic Pathology
• +۴ مورد دیگر

Dr. Anne Stowman is an Associate Professor at the University of Vermont's Robert Larner, M.D. College of Medicine, where she serves as Director of Dermatopathology at the University of Vermont Medical Center (UVMMC) and Network Vice Chair for Anatomic Pathology for the UVM Health Network. In her leadership role, she oversees anatomic pathology laboratories and faculty across Vermont and New York. Dr. Stowman completed her medical degree at the University of Minnesota and residency in Anatomic and Clinical Pathology at the University of Virginia (UVA), followed by a Fellowship in Dermatopathology at UVA. After working in private practice at a dermatopathology lab in Charlottesville, she joined the faculty at UVMMC and the Larner College of Medicine in 2017. Her research focuses on dermatopathology with particular emphasis on: Melanoma diagnostics and histopathology Applications of immunohistochemistry in skin pathology Educational case studies in dermatopathology Pathology laboratory management and cybersecurity Dr. Stowman's publication record spans from 2016 to 2023, demonstrating consistent scholarly activity across clinical dermatopathology, educational case reports, and operational aspects of pathology practice. Her work bridges clinical diagnostics with healthcare policy considerations, as evidenced by her contributions to discussions about remote diagnostics in pathology. As an educator, Dr. Stowman plays a significant role in training: Pathology residents Dermatology residents Medical students at UVM She directs a high-volume dermatopathology practice that services multiple private practice dermatology groups, hospital-based dermatology, the University Cancer Center, and Network hospitals, providing extensive clinical training opportunities for trainees.

• Cancer metabolism
• Tumor microenvironment
• Breast cancer
• +۵ مورد دیگر

Professor Federica Sotgia is a distinguished researcher in the School of Science, Engineering & Environment at the University of Salford, where she has been a faculty member since 2016. Previously, she served as a Senior Lecturer at the University of Manchester's Institute of Cancer Sciences (2012-2016) and as an Assistant Professor in the Department of Cancer Biology at Thomas Jefferson University's Kimmel Cancer Center (2006-2012). Her academic journey began with a postgraduate degree in Medical Genetics from the University of Genova, Italy in 2001, followed by post-doctoral training at Albert Einstein College of Medicine in New York. Dr. Sotgia's research focuses on cancer metabolism and the tumor microenvironment, with particular emphasis on breast cancer. Her work investigates how metabolic alterations in stromal cells influence tumor growth and progression. She has made significant contributions to understanding the role of mitochondrial metabolism in cancer stem cells and has pioneered research on repurposing FDA-approved drugs for targeting tumor-initiating cells. Her laboratory employs sophisticated techniques for studying cellular metabolism, senescence, and cancer progression. Analysis of her recent publications (2020-2024) reveals consistent focus on cancer stem cells, mitochondrial metabolism, and therapeutic targeting. Her research demonstrates how metabolic reprogramming, particularly involving ATP production and mitochondrial function, drives cancer progression and resistance. She has identified several FDA-approved drugs that can be repurposed to target cancer stem cells, bridging basic science with potential clinical applications. Dr. Sotgia's teaching responsibilities align with her research expertise, covering cancer biology, cancer metabolism, biochemistry, and drug discovery. Her mentorship likely emphasizes the translational aspects of cancer research, connecting molecular mechanisms with therapeutic strategies. Her research program demonstrates strong continuity and evolution from her early discovery of caveolin-3 gene mutations causing limb-girdle muscular dystrophy to her current focus on cancer metabolism. This trajectory shows how fundamental discoveries in cell biology can inform our understanding of disease mechanisms across different conditions.

• Nuclear Medicine
• Thyroid Cancer Imaging
• PET/CT Diagnostics
• +۴ مورد دیگر

Funda ÜSTÜN is a Professor at Trakya University Medical Faculty's Department of Nuclear Medicine with extensive expertise in molecular imaging applications for cancer diagnostics and therapy. Her clinical and research focus centers on thyroid cancer imaging, prostate cancer diagnostics using PSMA-targeted radiopharmaceuticals, and sarcoma research. Her research interests span Nuclear Medicine, Thyroid Cancer Imaging, PET/CT Diagnostics, Prostate Cancer Imaging, Radiopharmaceutical Development, Sarcoma Research, and Molecular Imaging. She investigates advanced imaging techniques for cancer characterization, develops novel radiopharmaceuticals for targeted therapy, and applies machine learning to improve cancer risk stratification. Her work bridges nuclear medicine with oncology, endocrinology, and nanotechnology to enhance diagnostic accuracy and therapeutic outcomes. Her recent publications demonstrate strong trends in precision oncology, with emphasis on PSMA imaging for prostate cancer, thyroid cancer recurrence prediction using AI, and nanoparticle-based drug delivery systems. Key research areas include radiopharmaceutical development, molecular imaging biomarkers, and quantitative imaging analysis for tumor characterization. As an academic advisor, she has supervised multiple master's theses focusing on PET/CT applications in prostate cancer, lung metastasis prediction, and parathyroid scintigraphy. Her editorial and referee work includes contributions to MIRT (Molecular Imaging and Radiotherapy). Her laboratory and research team focus on preclinical radiopharmaceutical development, molecular imaging techniques, and translational applications of nuclear medicine in oncology. Current projects involve nanoparticle-based drug delivery systems, radiolabeling techniques, and advanced PET/CT quantification methods for cancer diagnostics.

• Oncology
• Gastroenterology
• Molecular Pathology
• +۳ مورد دیگر

Clinical Associate Professor Rikke Karlin Jepsen is affiliated with the Department of Clinical Medicine at the University of Copenhagen's Faculty of Health and Medical Sciences. Based at Rigshospitalet (Blegdamsvej 3, Copenhagen), she maintains a clinical-academic role through Region Hovedstaden (email: rikke.karlin.jepsen@regionh.dk). Her research focuses on colorectal cancer pathogenesis and diagnostics, with particular expertise in tumor heterogeneity , microRNA biomarkers , and population-based cancer registries . Recent work analyzes serrated polyp pathways (2023-2024), while earlier studies investigate molecular predictors of lymph node metastasis (2016) and surgical staging improvements (2012). Analysis of her publication trends reveals strong emphasis on translational oncology , bridging molecular pathology with clinical epidemiology. Her register-based cohort studies leverage Denmark's national healthcare databases for large-scale cancer research, while molecular work examines microRNA gradients as potential diagnostic tools. Current research collaborations prominently feature Gögenur, Kuhlmann, and Klein across multiple publications, indicating sustained teamwork in gastrointestinal oncology.

• Lung pathology
• Pulmonary fibrosis
• Lung cancer
• +۷ مورد دیگر

Robert Homer, MD, PhD is Professor of Pathology and of Medicine (Pulmonary) at Yale School of Medicine, where he serves as Director of Medical Studies for Anatomic Pathology and Director of Medical Education for Pathology. He previously served as lead thoracic pathologist at Yale from 2004 to 2022 and Director of Anatomic Pathology at VA Connecticut HealthCare system from 1994 to 2022. His institutional affiliations include multiple Yale centers and programs such as the Cancer Signaling Networks, Center for Thoracic Cancers, Interstitial Lung Disease Program, and Pulmonary, Critical Care & Sleep Medicine. Dr. Homer's research focuses on the pathology of neoplastic and inflammatory lung diseases, with particular expertise in pulmonary fibrosis and lung cancer mechanisms. His work bridges basic science and clinical pathology, utilizing both human tissue analysis and murine models of lung disease. He has recently become interested in applying Large Language Models to medical education, reflecting his dual commitment to pathology research and pedagogy. Analysis of Dr. Homer's recent publications (2022-2025) reveals a strong focus on lung cancer genomics, tumor evolution mechanisms, and the molecular basis of pulmonary fibrosis. His work frequently appears in high-impact journals including Nature, Nature Communications, and Cancer Discovery, demonstrating significant contributions to understanding lung disease pathogenesis and developing improved diagnostic approaches. Keynote address for Pulmonary Pathology Society (2009) Dr. Homer maintains an active research program despite being in phased retirement, with numerous publications through 2025. He serves as an editorial board member for the American Journal of Pathology and has presented on innovative approaches to medical education, including 'From Bots to Docs, Harnessing AI in the medical education journey' (2023). His clinical expertise in thoracic pathology continues to inform both his research and teaching activities at Yale.

• Musculoskeletal Oncology
• Bone Sarcomas
• Soft Tissue Sarcomas
• +۵ مورد دیگر

Dieter Lindskog, MD, is an Associate Professor of Orthopaedics and Rehabilitation at Yale School of Medicine and Section Chief of Musculoskeletal Oncology. He serves as Disease Aligned Research Team Leader for the Sarcoma Program at Yale Cancer Center and directs the Smilow Cancer Hospital Sarcoma Tumor Board. Dr. Lindskog's clinical practice is directed nearly full-time at the treatment of patients with orthopaedic oncologic disease including sarcomas and metastatic disease to bone, a rare specialty in the medical field. Dr. Lindskog's research focuses on clinical study of patients with malignant and benign bone and soft tissue tumors. His investigations include evaluating outcomes for different reconstructive techniques after sarcoma resections and minimally invasive techniques for treating benign bone lesions. Recent work has centered on periacetabular osteolytic metastases and the AORIF (Ablation-Osteoplasty-Reinforcement-Internal Fixation) procedure, which has shown promise for pain management and functional preservation. His publication record demonstrates consistent scholarly output in high-impact journals including Cancers , Radiology , and Journal of Clinical Medicine , with research spanning surgical techniques, comparative outcomes, and natural history studies of musculoskeletal tumors. The publication trends show increasing focus on metastatic bone disease management and minimally invasive approaches to complex oncologic problems. Dr. Lindskog maintains active leadership roles in professional organizations: National Comprehensive Cancer Network – Bone Cancer Panel Member (2015-Present) AAOS Musculoskeletal Tumor & Metabolic Disease Program Committee (2017-Present) Musculoskeletal Tumor Society Fellowship Committee member (2016-Present) YNHH Orthopedic Residency Associate Program Director (2015-Present) As an educator, Dr. Lindskog contributes to medical student education through orthopaedic surgery clerkships and serves as Associate Program Director for the orthopaedic residency program. His clinical expertise in bone and soft tissue sarcoma represents a specialized area within orthopaedics that deals with 'life and death issues,' as he describes it, distinguishing it from much of general orthopaedic practice.